(Q34996351)

5 August 2017

1 reference

title

The myelodysplastic syndromes: morphology, risk assessment, and clinical management (2002). (English)

1 reference

5 August 2017

John M Bennett

1

1 reference

5 August 2017

Peter A Kouides

series ordinal

2

1 reference

5 August 2017

Stephen J Forman

series ordinal

3

1 reference

5 August 2017

language of work or name

1 reference

1 August 2002

1 reference

International Journal of Hematology

5 August 2017

published in

1 reference

5 August 2017

volume

76 Suppl 2

1 reference

5 August 2017

page(s)

228-238

1 reference

Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology?

5 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF03165122

Proposals for the classification of the myelodysplastic syndromes

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF03165122

Issues in the pathology and diagnosis of the chronic myeloproliferative disorders and the myelodysplastic syndromes

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF03165122

Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies

21 January 2018

1 reference

12 December 2020

1 reference

12 December 2020

High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens.

1 reference

12 December 2020

Antithymocyte globulin for patients with myelodysplastic syndrome

1 reference

12 December 2020

Clinical features of MDS

1 reference

12 December 2020

Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes.

1 reference

12 December 2020

Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia

1 reference

12 December 2020

Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age.

1 reference

12 December 2020

Low-dose cyclosporin for severe aplastic anemia

1 reference

12 December 2020

Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy

1 reference

12 December 2020

Amifostine stimulates formation of multipotent and erythroid bone marrow progenitors

1 reference

12 December 2020

Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients

1 reference

12 December 2020

Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score.

1 reference

12 December 2020

Report of an international working group to standardize response criteria for myelodysplastic syndromes.

1 reference

12 December 2020

The 5q- syndrome: a single-institution study of 43 consecutive patients.

1 reference

12 December 2020

Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes

1 reference

12 December 2020

Percentages of bone marrow blasts and chromosomal changes in patients with refractory anemia help to determine prognoses

1 reference

12 December 2020

Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome.

1 reference

12 December 2020

Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients

1 reference

12 December 2020

The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group

1 reference

12 December 2020

Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation

1 reference

12 December 2020

Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS.

1 reference

12 December 2020

Pentoxifylline and ciprofloxacin in patients with myelodysplastic syndrome. A phase II trial

1 reference

12 December 2020

Chronic myelomonocytic leukaemia (CMML)--a myelodysplastic or myeloproliferative syndrome?

1 reference

12 December 2020

Erythropoietin, with and without granulocyte-colony stimulating factor (G-CSF), in the treatment of myelodysplastic syndrome (MDS) patients

1 reference

12 December 2020

Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles

1 reference

12 December 2020

Standard and low-dose chemotherapy for the treatment of myelodysplastic syndromes

1 reference

12 December 2020

Abnormal localization of immature precursors (ALIP) in the bone marrow of myelodysplastic syndromes: Current state of knowledge and future directions

1 reference

12 December 2020

Morphologic classification of the myelodysplastic syndromes (MDS): Combined utilization of bone marrow aspirates and trephine biopsies

1 reference

12 December 2020

Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors

1 reference

12 December 2020

Heterogeneity of acquired idiopathic sideroblastic anaemia (AISA)

1 reference

12 December 2020

Prognostic implication and characterization of the blast cell population in the myelodysplastic syndrome

1 reference

12 December 2020

Predominance of trisomy 1q in myelodysplastic syndromes in Korea: is there an ethnic difference? A 3-year multi-center study

1 reference

12 December 2020

Morphology and classification of the myelodysplastic syndromes and their pathologic variants

1 reference

12 December 2020

International scoring system for evaluating prognosis in myelodysplastic syndromes

1 reference

12 December 2020

Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia

1 reference

12 December 2020

Infliximab chimaeric anti-tumour necrosis factor alpha monoclonal antibody treatment for patients with myelodysplastic syndromes

1 reference

12 December 2020

Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia.

1 reference

12 December 2020

The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study

1 reference

12 December 2020

Apoptosis in myelodysplasia: a paradox or paradigm

1 reference

12 December 2020

Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases

1 reference

12 December 2020

Simultaneous assessment of cell kinetics and programmed cell death in bone marrow biopsies of myelodysplastics reveals extensive apoptosis as the probable basis for ineffective hematopoiesis

1 reference

12 December 2020

Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma

1 reference

12 December 2020

Hypocellular myelodysplastic syndromes (MDS): new proposals.

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03165122

1 reference

Dimensions Publication ID

5 August 2017

1043161627

0 references

1 reference